6
Participants
Start Date
August 26, 2024
Primary Completion Date
January 31, 2026
Study Completion Date
January 31, 2028
CRD3874
CRD3874-SI is a STING agonist. CRD3874 is a synthetic drug that activates STING, and STING stimulates the immune system to kill cancer cells. In experiments on blood from humans, CRD3874 makes blood cells produce molecules responsible for anti-cancer activity. CRD3874 was tested in mice with cancers including leukemia, head and neck cancer, lung cancer, pancreatic cancer and sarcoma. In these mice, CRD3874 made tumors shrink or disappear, and some mice developed long-lasting immunity against cancer.
University of Maryland, Baltimore, Baltimore
University of Maryland, Baltimore
OTHER